Abstract
We read with interest the exhaustive review by Yerushalmi and colleagues1 on the potential prognostic and predictive role of Ki67 expression in breast cancer. The authors conclude that, at present, Ki67 cannot be used as a tool for selecting specific chemotherapy or endocrine treatment, nor for assigning patients to specific risk groups. They recommend the adoption of standard methods and cutoff points in interpreting immunohistochemical specimens. Similar conclusions were drawn in other reviews,2,3 with the reported cutoffs for Ki67 ranging from 3·5 to 34%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
